AnaptysBio (ANAB) 10-Q2023 Q1 Quarterly report

Filed: 11 May 23, 4:19pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: abrocitinib, ACR, Actemra, Adbry, amlitelimab, array, asthma, atopy, Bausch, biology, blinded, broader, central, certified, Chancery, choice, compelling, COPD, CPPA, deeper, depository, doctrine, DOJ, doubt, Dupixent, duty, Elidel, enumerated, Eric, exploring, facially, forum, fullest, Galderma, IGA, inapplicable, Innate, Kevzara, lebrikizumab, legacy, LEO, loan, Loumeau, mast, nemolizumab, orchestrate, Orencia, organizational, par, Pfizer, Pharma, pooled, profession, proliferation, Protopic, RA, repurchase, repurchased, retired, Rinvoq, Rituxan, Roche, RSU, Sanofi, subcutaneously, thereunder, unblinded, underlying, upstream, waive, white, Xeljanz

Removed: abbreviated, Accountability, acid, ADC, administering, aminotransferase, approach, approving, aspartate, assist, AST, Australia, baricitinib, BCMA, belantamab, BPCIA, Celgene, CGI, Classification, cleared, clinically, cohort, combining, comorbidity, confirmed, contracted, conversion, correlated, COVID, CPK, creatine, criterion, CTA, defective, designate, designated, designing, diagnosed, diagnostic, dibutyl, dinitrochlorobenzene, diphencyprone, DLQI, Erythema, ester, exceeded, excluding, expression, Festival, Genotypic, head, HNSCC, hypermutation, identifying, importance, Importantly, impression, infusion, inhibited, injection, Innovation, interchangeable, inupadenant, investigator, IQVIA, IRR, Japanese, journey, justified, Kingdom, larger, line, local, lowest, mafodotin, marketplace, MCID, mild, minimal, moderate, moiety, neck, Notification, occupied, overcome, periodically, phosphokinase, Portability, qualify, quarantined, RADIANCE, Reacquisition, recovered, reference, regional, registry, released, replicate, rescue, reserved, residual, resignation, Revision, ruxolitinib, sBTLA, scalp, secondary, selected, sequelae, shed, shedding, shorten, similarity, soluble, somatic, sporadically, squaric, Squibb, STING, stream, substituted, substitution, sufficiently, superior, surface, symptomatic, tofacitinib, toxoid, traditional, ultimate, underwriting, undisclosed, unique, validated, withdrawn

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

ANAB similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

I, Dennis Mulroy, Chief Financial Officer of AnaptysBio, Inc. (Company), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

•the Quarterly Report on Form 10-Q of the Company for the quarter ended March 31, 2023 (the “Report”), as filed with the Securities and Exchange Commission, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

•the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.

Date: May 11, 2023


/s/ Dennis Mulroy
Dennis Mulroy
Chief Financial Officer
(Principal Financial Officer)